Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.

Chi-Jung WuPei-Chang LeeYa-Wen HungChieh-Ju LeeChen-Ta ChiI-Cheng LeeMing-Chih HouYi-Hsiang Huang

Published in: Cancer immunology, immunotherapy : CII (2022)

A high DCR was observed by lenvatinib/pembrolizumab combination without adverse effect on ALBI score for systemic therapy-naïve and -experienced uHCC. Suboptimal response to prior nivolumab-failed patients requires further exploration.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
advanced non small cell lung cancer
prognostic factors
peritoneal dialysis
stem cells
locally advanced
mesenchymal stem cells
patient reported outcomes
rectal cancer
cell therapy